Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M H Davidson

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Atherosclerosis|June 28, 2001
Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemiaW Insull, M Koren, J Davignon, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|May 1, 1995
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitorJ W Nawrocki, S R Weiss, M H Davidson, et al.
Journal of Clinical Pharmacology|January 6, 2001
Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging studyC A Dujovne, H Bays, M H Davidson, et al.
Atherosclerosis|January 20, 1995
The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patientsW Insull, M H Davidson, D M Demke, et al.
The American Journal of Cardiology|August 26, 1998
Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study GroupE A Stein, M H Davidson, A S Dobs, et al.
JAMA|January 26, 1999
Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trialM H Davidson, J Hauptman, M DiGirolamo, et al.
Regulatory Toxicology and Pharmacology : RTP|February 1, 1996
Panel discussion: what is the future of macronutrient substitutes in North America?J F Borzelleca, M Cheney, M H Davidson, et al.
JAMA|January 10, 1996
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemiaR G Bakker-Arkema, M H Davidson, R J Goldstein, et al.
The American Journal of Clinical Nutrition|March 13, 1998
Long-term effects of consuming foods containing psyllium seed husk on serum lipids in subjects with hypercholesterolemiaM H Davidson, K C Maki, J C Kong, et al.
Current Medical Research and Opinion|July 24, 2001
A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trialD R Illingworth, J R Crouse, D B Hunninghake, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Atherosclerosis|June 28, 2001
Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemiaW Insull, M Koren, J Davignon, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|May 1, 1995
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitorJ W Nawrocki, S R Weiss, M H Davidson, et al.
Journal of Clinical Pharmacology|January 6, 2001
Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging studyC A Dujovne, H Bays, M H Davidson, et al.
Atherosclerosis|January 20, 1995
The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patientsW Insull, M H Davidson, D M Demke, et al.
The American Journal of Cardiology|August 26, 1998
Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study GroupE A Stein, M H Davidson, A S Dobs, et al.
JAMA|January 26, 1999
Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trialM H Davidson, J Hauptman, M DiGirolamo, et al.
Regulatory Toxicology and Pharmacology : RTP|February 1, 1996
Panel discussion: what is the future of macronutrient substitutes in North America?J F Borzelleca, M Cheney, M H Davidson, et al.
JAMA|January 10, 1996
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemiaR G Bakker-Arkema, M H Davidson, R J Goldstein, et al.
The American Journal of Clinical Nutrition|March 13, 1998
Long-term effects of consuming foods containing psyllium seed husk on serum lipids in subjects with hypercholesterolemiaM H Davidson, K C Maki, J C Kong, et al.
Current Medical Research and Opinion|July 24, 2001
A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trialD R Illingworth, J R Crouse, D B Hunninghake, et al.
Pageof 7